Oncology JP Morgan Week 2025 – Marianne De Backer At JPM 2025, pharmaphorum editor-in-chief Jonah Comstock spoke with Vir Biotechnology CEO Marianne De Backer.
R&D JP Morgan 2024 – Marianne De Backer Vir Biotechnology made headlines in 2021 for its work with GlaxoSmithKline on a treatment for COVID-19, and again in 2022 for its work with the US government on influenza.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
